Lineage Cell Therapeutics Inc
Veridion Score
Composite trend over time
Why is LCTX moving today?
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
Real vendor fields plus Veridion-computed history. Missing fields stay blank.
Warehouse intelligence for LCTX.
LCTX insider activity
Lineage Cell Therapeutics Inc
No multi-insider buying cluster in the last 90 days
Net selling: -$4K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-12 | 2026-03-12 | Culley Brian M | Insider | buy | $1.63 | 15,000 | 255,516 | $24K | SEC Form 4 |
| 2026-02-13 | 2026-02-11 | Samuel George A. III | Insider | sell | $1.80 | 2,502 | 31,063 | $5K | SEC Form 4 |
| 2026-02-13 | 2026-02-11 | Culley Brian M | Insider | sell | $1.80 | 12,869 | 240,516 | $23K | SEC Form 4 |
| 2025-12-19 | 2025-12-19 | Samuel George A. III | Insider | sell | $1.68 | 65 | 27,490 | $109 | SEC Form 4 |
| 2025-12-19 | 2025-12-19 | Culley Brian M | Insider | sell | $1.68 | 334 | 222,135 | $561 | SEC Form 4 |
LCTX contract awards, year to date.
Public federal awards linked to this ticker.
LCTX lobbying filings, year to date.
Registered lobbying filings matched to Lineage Cell Therapeutics Inc.